|
|
|
| The Business Of CNS with Acumen's Jim Doherty, Ph.D. | The Business of Biotech welcomes Acumen Pharmaceuticals' Dr. Jim Doherty for a discussion on the challenges and advances in Alzheimer's therapeutics, including controversies around amyloid-targeting drugs, the role of biomarkers in personalized treatment, and Acumen's lead candidate, Sabirnetug. Listen now and subscribe so you never miss an episode! |
|
|
|
|
Exsilio Therapeutics’ CEO Tal Zaks, previously CMO at Moderna, explains his philosophy that scientific curiosity is fundamental to groundbreaking drug development. |
|
|
|
|
|
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|